Last reviewed · How we verify
abciximab intracoronary
Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.
Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation. Used for Acute coronary syndrome undergoing percutaneous coronary intervention, Prevention of ischemic complications in patients undergoing coronary angioplasty.
At a glance
| Generic name | abciximab intracoronary |
|---|---|
| Sponsor | University of Leipzig |
| Drug class | Glycoprotein IIb/IIIa inhibitor |
| Target | Glycoprotein IIb/IIIa integrin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Abciximab binds irreversibly to the glycoprotein IIb/IIIa integrin receptor on platelets, which is the final common pathway for platelet aggregation. By blocking this receptor, it prevents fibrinogen and von Willebrand factor from cross-linking platelets, thereby inhibiting platelet clumping. This mechanism is particularly effective in acute coronary syndromes and during percutaneous coronary intervention to reduce thrombotic complications.
Approved indications
- Acute coronary syndrome undergoing percutaneous coronary intervention
- Prevention of ischemic complications in patients undergoing coronary angioplasty
Common side effects
- Bleeding
- Thrombocytopenia
- Back pain
- Hypotension
Key clinical trials
- Deferred Stenting in Patients With Anterior Wall STEMI (NA)
- Efficacy and Safety Study of Deferred Stenting in Patients With STEMI (NA)
- A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab (PHASE3)
- A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function (NA)
- The INFUSE - Anterior Myocardial Infarction (AMI) Study (NA)
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI (PHASE4)
- Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI (PHASE4)
- Intracoronary Abciximab With Clearway Catheter (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- abciximab intracoronary CI brief — competitive landscape report
- abciximab intracoronary updates RSS · CI watch RSS
- University of Leipzig portfolio CI